This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WILLIAM M. M. KIRBY, M.D.; DEAN G. HUDSON, M.D.; WARD D. NOYES, M.D.

AMA Arch Intern Med. 1956;98(1):1-7.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Novobiocin is a new antibiotic isolated independently by three different groups of workers.¹ The names given to this antibiotic, and the companies under whose supervision it was discovered, are as follows: Cathomycin (Merck); streptonivicin (Albamycin) (Upjohn); and Cardelmycin (Pfizer). Preliminary in vitro studies have shown that the antibiotic is active against the commonly encountered Gram-positive bacteria and also against certain Gram-negatives.² Of particular importance is the fact that staphylococci resistant to other antibiotics are highly susceptible to Novobiocin. Experimental infections in animals have also indicated a high degree of activity with little toxicity.³ Laboratory studies and a clinical trial in 75 patients comprise the present report.*

Methods

Sensitivity Tests.

—Concentrations of novobiocin causing inhibition of growth of streptococci and pneumococci were determined in tryptose phosphate broth containing 3% human blood; 0.5 ml. amounts of a 10^-4 dilution of an overnight culture were added to equal amounts . . . [Full Text PDF of this Article]

Author Affiliations
Seattle

From the Department of Medicine, University of Washington School of Medicine, and the King County Hospital.

Footnotes
Submitted for publication Feb. 4, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?